The rare but very serious condition of malignant hyperthermia (MH) remains a risk at all surgical facilities, including ambulatory surgical centers (ASCs). MH occurs in about one in 50,000 adults under anesthesia, and one in about 12,000 children, which translates to one or two deaths annually in the United States. When it does strike, MH often is fatal if not treated within minutes. And the only antidote is a very expensive drug.
However, new research on vulnerable populations and new treatment options are making it easier to stay ahead of the probability curve. For ASCs, with their slender financial margins and focus on surgery, to continue to make MH a “never event” requires constant awareness.
Several organizations have issued guidelines on MH, including the American Society of PeriAnesthesia Nurses (ASPAN), Cherry Hill, New Jersey; the Malignant Hyperthermia Association of the United States (MHAUS), Sherburne, New York; the American Society of Anesthesiologists (ASA), Schaumburg, Illinois; and AORN, Denver. All stress the importance of preparedness, awareness, and immediate response to symptoms.
The condition first surfaced in Australia in 1960, when 10 members of the same extended family died during surgery with general anesthesia. An investigation showed that malignant hyperthermia appeared to be inherited as a dominant trait, and researchers subsequently associated it with mutations in about 20 different genes. The most recent research has linked the condition to mutations in the RYR1 and SEPN1 genes.
Afflicted patients’ muscles become stiff rather than relaxed under anesthesia, breathing accelerates instead of slowing, irregular heartbeats follow while blood pressure falls, and body temperature rises rapidly, reaching more than 108°F. The muscles release acid and potassium in amounts large enough to cause cardiac damage or death.
The only known antidote is dantrolene sodium.
Pigs tend to be susceptible to MH, and scientists conducting experiments with them in 1975 found that dantrolene relaxed muscles, lowered body temperature, and halted acid production without damaging the heart. The primary triggers, they found, were sevoflurane, halothane, and succinylcholine.
Following a clinical study in the late 1970s, the Food and Drug Administration (FDA) approved dantrolene for human use for MH.
Protocols call for stocking at least 36 vials, and the shelf life is 24 months, so keeping the drug on hand is expensive.
For patients susceptible to MH, there are safe alternatives, including local anesthetics, nitrous oxide, propofol, and ketamine. Also safe are the non-depolarizing muscle relaxants such as pancuronium and vecuronium.
Screening candidates for elective surgery should go a long way toward identifying patients who are at risk for MH. In practice, however, there are limits. Other than relatives who have been stricken in the past, the best indicators are genetic testing and a muscle biopsy that only about 10 hospitals nationwide can perform.
To help assess risk, MHAUS maintains the North American Malignant Hyperthermia Registry and urges patients who have had MH episodes to submit their names and blood samples to aid in research.
Using the registry database, researchers have found that MH fatalities predominate in young, healthy patients having elective procedures. Such was the case in a Florida physician’s office in 2008, in fact, which led to heightened nationwide scrutiny of nonhospital incidents of MH.
During a recent unannounced survey at a midwestern ASC, inspectors noted that the required 36 vials of dantrolene sodium were located not in the ASC’s OR, but in other areas and at the nearby affiliated hospital.
The ASC changed its policy to keep the dantrolene sodium on site, but plans to replace the drug with a newer version, which comes in premeasured syringes. It is concentrated, so the 36 vials can be replaced with just three syringes on site.
The experience also highlighted the fact that because of its hereditary nature, MH has spread among certain populations and across particular geographical areas.
ASCs report that surveyors from the Centers for Medicare & Medicaid Services (CMS) are watching for MH in particular in four states: Michigan, Nebraska, West Virginia, and Wisconsin. However, according to a CMS spokeswoman, the agency is not currently conducting a formal investigation.
Other published research indicates the condition is more likely in those of northern European extraction, such as the Scandinavian, German, and Czech residents of those states. Higher MH rates also affect Japan, Australia, and New Zealand.
In its guidelines, ASPAN also warns of nonsurgical risk factors such as muscular dystrophy and sensitivity to heat.
According to AORN, between one in 30,000 and one in 37,000 people may be susceptible to MH, and the 2008 Perioperative Standards and Recommended Practices manual includes an extensive guideline for MH.
“Nursing care begins when the patient is scheduled for any procedure involving general anesthesia,” the guideline says. The nurse should begin by asking the patient and family about past experience:
• Has anyone ever told you that you had a bad reaction to anesthesia?
• Has anyone ever told you that you or a family member had a problem with anesthesia?
• Have you or a family member experienced a high fever while under anesthesia?
• Has anyone in your family died unexpectedly in the operating room?
If the answers indicate susceptibility to MH, the nurse should notify the surgeon and anesthesiologist. In an ASC or other facility without critical care services, AORN recommends making advance arrangements for transfer to a hospital.
Symptoms associated with anesthesia include increased carbon dioxide levels and a decrease in arterial oxygen saturation, irregular or rapid heart rhythm, muscle spasm, and muscle rigidity.
A rise in temperature may follow, but not always, according to ASPAN guidelines. The definitive sign, ASPAN says, is rigidity of the trunk or limbs. “Begin treatment immediately,” it directs.
Dantrolene sodium is still the only known antidote for MH, but a new version makes it easier to stock and use the drug, which must be kept near the OR and administered within 10 minutes of the onset of symptoms. The most commonly used brands are Dantrium (Procter & Gamble Pharmaceuticals, Cincinnati) and Revonto (US WorldMeds, Louisville).
In July 2014, the FDA approved a new formulation, Ryanodex (Eagle Pharmaceuticals, Woodcliff Lake, New Jersey), for use in treating MH. Its main advantage, according to the company, is its higher solubility.
Other forms of dantrolene sodium come in 20-mg vials, and each facility must stock at least 36 vials, the recommended amount to treat a 70-kg person. Before use, each vial must be dissolved in 60 mL of sterile water for injection through a large vein.
In contrast, a 250-mg vial of Ryanodex can be prepared in only 5 mL of sterile water for injection, so it is easier and faster to administer.
MHAUS, in a comment on its website, notes that the cost of dantrolene sodium is a small price to pay given its life-saving property. Like a defibrillator, dantrolene sodium proves its worth by being there when needed.
In any case, failing to have the necessary vials on hand may result, at the very least, in a survey citation. ✥
AORN. Perioperative Standards and Recommended Practices. Malignant Hyperthermia Guideline. Denver, CO: AORN, 2008. www.aorn.org.
Kassulke S. Malignant hyperthermia. A competence-based orientation and credentialing program for the registered nurse in the perianesthesia setting. Chapter 14. Cherry Hill, NJ: ASPAN, 2014:345-358.
Malignant Hyperthermia Association of the United States. Emergency therapy for malignant hyperthermia. www.mhaus.org.
Shah M. New malignant hyperthermia antidote: Convenience worth the cost? Drug Topics. Published online April 10, 2015. http://drugtopics.modernmedicine.com.